Fast track — ArticlesClopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial
Introduction
Atrial fibrillation is a common cardiac arrhythmia, especially in the elderly, and affects over 1% of the population. It increases the risk of stroke and other vascular events.1, 2 Oral anticoagulation therapy such as warfarin reduces stroke by two-thirds compared with no treatment.3, 4 Compared with aspirin, oral anticoagulation therapy reduces the risk of stroke by 45% and reduces cardiovascular events by 29%.5 However, it increases the risk of major bleeding by about 70%5 compared with aspirin. Oral anticoagulation therapy is currently the treatment of choice for patients at high risk of stroke.6
The response to oral anticoagulation therapy is affected by gut flora, variations in hepatic function, interactions with several drugs, and diet,7 requiring regular monitoring of the level of anticoagulation. Therefore, only about half of potentially eligible patients receive oral anticoagulation therapy.8 An effective, simple and safe alternative to this treatment could be of great clinical value.
Both aspirin and clopidogrel are antiplatelet agents that act through different mechanisms and are effective in preventing vascular events in patients at high risk.9 Aspirin reduces risk of stroke in patients with atrial fibrillation by 22%.3, 4 The additive benefits of combining a thienopyridine with aspirin have been clearly shown in patients undergoing percutaneous coronary intervention, in those with acute coronary syndrome or acute myocardial infarction.10, 11, 12, 13 Since aspirin has a documented protective effect in atrial fibrillation, it is reasonable to expect that the addition of clopidogrel to aspirin will provide incremental benefits so that this combination would be non-inferior to oral anticoagulation therapy alone in preventing vascular events. We aimed to assess whether clopidogrel plus aspirin was statistically non-inferior to oral anticoagulation therapy for prevention of vascular events in patients with atrial fibrillation at high risk of stroke and eligible for oral anticoagulation therapy.
Section snippets
Participants
Three separate inter-related trials comprise the ACTIVE programme. Patients eligible for and willing to take oral anticoagulation therapy were enrolled into ACTIVE W, in which clopidogrel plus aspirin was compared to oral anticoagulation therapy Patients ineligible for or unwilling to take oral anticoagulation therapy were enrolled into ACTIVE A, in which clopidogrel was compared with placebo in patients receiving aspirin. ACTIVE I was a randomised placebo-controlled trial of irbesartan for
Results
Patients were enrolled between June, 2003, and December, 2004. Patient enrolment was briefly re-opened in July, 2005, because overall event rates were lower than expected. On August 25, 2005, the data and safety monitoring board recommended that the study be stopped due to clear evidence of superiority of oral anticoagulation over clopidogrel plus aspirin. Investigators were notified to discontinue study medication and to treat study patients according to current guidelines. The data and safety
Discussion
We have shown that oral anticoagulation therapy is superior to clopidogrel plus aspirin for prevention of vascular events in patients with atrial fibrillation at high risk of stroke who do not have contraindications to oral anticoagulation therapy. This finding was driven largely by higher rates of stroke and non-CNS systemic embolus with clopidogrel plus aspirin. Stroke and non-CNS systemic embolus are thought to result predominantly from cardiac thrombus formation in patients with atrial
References (19)
- et al.
ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients with Atrial Fibrillation)
J Am Coll Cardiol
(2001) - et al.
Oral anticoagulants. Mechanism of action, clinical effectiveness, and optimal therapeutic range
Chest
(1998) - et al.
Platelet-active drugs. The relationships among dose effectiveness, and side effects
Chest
(1998) - et al.
Atrial fibrillation as an independent risk factor for stroke. The Framingham Study
Stroke
(1991) - et al.
Atrial fibrillation: A major contributor to stroke in the elderly. The Framingham Study
Arch Intern Med
(1987) Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials
Arch Intern Med
(1994)- et al.
Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis
Ann Intern Med
(1999) - et al.
Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis
JAMA
(2002) - et al.
Why do patients with atrial fibrillation not receive warfarin?
Arch Intern Med
(2000)
Cited by (1793)
Atrial fibrillation and stroke: State-of-the-art and future directions
2024, Current Problems in CardiologyDAPT Is Comparable to OAC Following LAAC With WATCHMAN FLX: A National Registry Analysis
2023, JACC: Cardiovascular InterventionsAntithrombotic Therapy for Primary and Secondary Prevention of Ischemic Stroke: JACC State-of-the-Art Review
2023, Journal of the American College of Cardiology
- ‡
Members listed at end of paper